在喘恶化中使用类似葡萄糖-1受体激动剂:应用高维代因果森林来识别子组
Tiansheng Wang1, Jeanny H Wang1, Alan C Kinlaw2
1Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
Pharmacoepidemiology and drug safety
|July 27, 2025
概括
类似葡萄糖-1受体激活剂 (GLP1RA) 显示出喘恶化的风险降低,特别是在多次全身类固醇处方显示的严重喘患者中. 这一发现有助于个性化治疗预测.
科学领域:
- 药理学和呼吸系统医学
- 医疗保健中的机器学习
- 在观察性研究中的因果推理.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP1RA) 显示出降低喘恶化 (AE) 风险的潜力.
- 确定从GLP1RA中获益最多的患者子组对于个性化医学至关重要.
- 之前使用代因果森林 (iCF) 的研究受到变量约束的限制.
研究的目的:
- 确定最有可能从GLP1RA中获益的患者子组,以减少喘恶化风险.
- 应用一个高维的代因果森林 (hdiCF) 算法来增强子组识别.
- 利用机器学习来发现喘药物治疗中的异质治疗效应 (HTEs).
主要方法:
- 使用MarketScan 2016-2020索赔数据来应用hdiCF算法.
- 建立了一个新用户队列,比较GLP1RA和硫氨酸尿素,包括患有喘的患者.
- 在6个月内使用599个高维特征评估急性喘恶化.
主要成果:
- 使用GLP1RA与整体人群中AE风险降低有关 (aRD-1.4%).
- 该hdiCF算法根据系统性类固醇处方填充 (0, 1 和 ≥2) 确定了三个子组.
- 患有≥2次全身类固醇处方的患者显示GLP1RA的最大益处 (aRD -3.8%).
结论:
- 通过hdiCF的自动特征识别有效地确定了HTEs的临床相关子组.
- 系统性类固醇的处方量作为严重喘的代理,指导个性化的GLP1RA益处预测.
- 这种方法提高了对GLP1RA在特定喘患者群体的短期疗效的理解.
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:24Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
01:20Asthma: Pathogenesis and Management
597
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
597
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
464
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
464
01:29Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K